Physician profile
John Bisbee Johnson
NPI 1790709103
$4,773.53
in general payments reported to CMS, 2019-2025
37 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $729 · 2021: $1,063 · 2022: $855 · 2023: $528 · 2024: $183 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $748.83 | 2019-2025 | Zepbound, Mounjaro, Trulicity |
| Amgen INC. | $571.60 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $347.17 | 2019-2024 | Farxiga, Bevespi Aerosphere |
| Abbvie INC. | $336.23 | 2021-2025 | |
| Novo Nordisk INC | $331.44 | 2019-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $246.80 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $205.00 | 2020-2021 | |
| Pfizer INC. | $204.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.11 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $154.08 | 2019-2023 | |
| Amarin Pharma, INC. | $150.63 | 2019 | |
| Corcept Therapeutics | $143.95 | 2019-2021 | |
| Alkermes, INC. | $132.18 | 2019 | |
| Merck Sharp & Dohme LLC | $125.21 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $110.59 | 2021-2024 | Gvoke Hypopen |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.